NASDAQ:ZLAB Zai Lab (ZLAB) Stock Price, News & Analysis → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free ZLAB Stock Alerts $21.55 +0.03 (+0.14%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$21.00▼$21.8250-Day Range$13.72▼$21.5552-Week Range$13.48▼$37.92Volume395,874 shsAverage Volume668,242 shsMarket Capitalization$2.14 billionP/E RatioN/ADividend YieldN/APrice Target$64.22 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Zai Lab alerts: Email Address Zai Lab MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside198.0% Upside$64.22 Price TargetShort InterestBearish4.39% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.69Based on 18 Articles This WeekInsider TradingSelling Shares$208,508 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.14) to ($2.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.11 out of 5 starsMedical Sector594th out of 928 stocksPharmaceutical Preparations Industry282nd out of 431 stocks 3.5 Analyst's Opinion Consensus RatingZai Lab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZai Lab has only been the subject of 1 research reports in the past 90 days.Read more about Zai Lab's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.39% of the outstanding shares of Zai Lab have been sold short.Short Interest Ratio / Days to CoverZai Lab has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Zai Lab has recently increased by 6.86%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldZai Lab does not currently pay a dividend.Dividend GrowthZai Lab does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZLAB. Previous Next 2.6 News and Social Media Coverage News SentimentZai Lab has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Zai Lab this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for ZLAB on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zai Lab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $208,508.00 in company stock.Percentage Held by InsidersOnly 5.23% of the stock of Zai Lab is held by insiders.Percentage Held by Institutions41.65% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zai Lab's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zai Lab are expected to grow in the coming year, from ($3.14) to ($2.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zai Lab is -6.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zai Lab is -6.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZai Lab has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zai Lab's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin AnalyticsDid Intel Just Dethrone Nvidia?Intel (INTC) just announced a brand-new AI venture - the Aurora supercomputer. This computer was specifically designed for artificial intelligence and is now the fastest AI-centered computer on the planet. You can get all the details here. About Zai Lab Stock (NASDAQ:ZLAB)Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.Read More ZLAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZLAB Stock News HeadlinesMay 14 at 7:30 AM | businesswire.comZai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in ChinaMay 13 at 12:57 PM | marketwatch.comZai Lab Shares Rise 11% After Augtyro NDA Approved in ChinaMay 13 at 12:47 AM | stockhouse.comZai Lab Announces Approval of AUGTYRO(TM) (repotrectinib) for Patients with ROS1-positive NSCLC by China's NMPAMay 13 at 12:47 AM | markets.businessinsider.comChina Approves Zai Lab's AUGTYRO For ROS1-Positive NSCLC TreatmentMay 12 at 8:20 PM | businesswire.comZai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China's NMPAMay 12 at 4:03 AM | americanbankingnews.comZai Lab (NASDAQ:ZLAB) Shares Gap Down to $21.01May 11, 2024 | finance.yahoo.comZai Lab Limited (NASDAQ:ZLAB) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesMay 10, 2024 | finance.yahoo.comZai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call TranscriptMay 10, 2024 | americanbankingnews.comZai Lab (NASDAQ:ZLAB) Shares Gap Up Following Better-Than-Expected EarningsMay 9, 2024 | marketwatch.comZai Labs Shares Rise 26% After Narrower-Than-Expected 1Q LossMay 8, 2024 | investorplace.comZLAB Stock Earnings: Zai Lab Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | finance.yahoo.comZai Lab Announces First Quarter 2024 Financial Results and Recent Corporate UpdatesMay 8, 2024 | markets.businessinsider.comHere's what Wall Street expects from Zai Lab's earnings reportMay 7, 2024 | markets.businessinsider.comHere's what Wall Street expects from Zai Lab's earningsApril 30, 2024 | finance.yahoo.comZai Lab Limited's (NASDAQ:ZLAB) Profit OutlookApril 21, 2024 | wsj.comZai Lab Ltd. ADRApril 19, 2024 | finance.yahoo.comZai Lab Limited (ZLAB)April 16, 2024 | seekingalpha.comA Risky Bet: Zai Lab's Uncertain FutureApril 15, 2024 | businesswire.comZai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024April 15, 2024 | businesswire.comZai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024April 11, 2024 | finance.yahoo.comZai Lab Statement on Executive Management Team’s Agreement on Share ActivitiesApril 11, 2024 | businesswire.comZai Lab Statement on Executive Management Team's Agreement on Share ActivitiesApril 9, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)April 2, 2024 | businesswire.comZai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology ProgramsApril 1, 2024 | msn.comZai Lab reports Krazati lung cancer study meets primary endpointSee More Headlines Receive ZLAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/14/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ZLAB CUSIPN/A CIK1704292 Webwww.zailaboratory.com Phone862161632588Fax86-21-6163-2570Employees2,175Year FoundedN/APrice Target and Rating Average Stock Price Target$64.22 High Stock Price Target$73.34 Low Stock Price Target$47.50 Potential Upside/Downside+198.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-334,620,000.00 Net Margins-116.45% Pretax Margin-116.45% Return on Equity-40.21% Return on Assets-32.48% Debt Debt-to-Equity RatioN/A Current Ratio4.63 Quick Ratio4.43 Sales & Book Value Annual Sales$291.07 million Price / Sales7.35 Cash FlowN/A Price / Cash FlowN/A Book Value$8.05 per share Price / Book2.68Miscellaneous Outstanding Shares99,209,000Free Float94,020,000Market Cap$2.14 billion OptionableOptionable Beta1.11 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Ying Du Ph.D. (Age 58)Founder, Chairperson & CEO Comp: $1.67MMr. Joshua L. Smiley (Age 54)President & COO Comp: $647.11kDr. Rafael G. Amado M.D. (Age 60)President and Head of Global Oncology Research & Development Comp: $477kDr. Harald Reinhart M.D. (Age 72)President and Head of Global Development for Neuroscience, Autoimmune & Infectious Diseases Comp: $923.33kDr. Yajing Chen Ph.D.Chief Financial OfficerDr. Peter Huang Ph.D.Chief Scientific OfficerMs. Christine ChiouSenior VP & Head of Investor RelationsMr. Frazor Titus Edmondson III (Age 58)J.D., Chief Legal Officer & Corporate Secretary Comp: $829kMs. Ann E. Beasley J.D.Chief Compliance OfficerDr. Ning Xu M.D. (Age 59)Executive VP & Head of Clinical Operations More ExecutivesKey CompetitorsRocket PharmaceuticalsNASDAQ:RCKTArvinasNASDAQ:ARVNAmneal PharmaceuticalsNASDAQ:AMRXGeronNASDAQ:GERNDeciphera PharmaceuticalsNASDAQ:DCPHView All CompetitorsInsiders & InstitutionsCapital World InvestorsBought 465,337 shares on 5/14/2024Ownership: 5.730%Capital International Inc. CA Bought 5,815 shares on 5/14/2024Ownership: 0.093%Clearbridge Investments LLCSold 10,821 shares on 5/13/2024Ownership: 0.819%M&G PlcBought 454,128 shares on 5/10/2024Ownership: 0.458%Headlands Technologies LLCBought 3,971 shares on 5/8/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions ZLAB Stock Analysis - Frequently Asked Questions Should I buy or sell Zai Lab stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZLAB shares. View ZLAB analyst ratings or view top-rated stocks. What is Zai Lab's stock price target for 2024? 5 analysts have issued 12 month price objectives for Zai Lab's shares. Their ZLAB share price targets range from $47.50 to $73.34. On average, they anticipate the company's share price to reach $64.22 in the next twelve months. This suggests a possible upside of 198.0% from the stock's current price. View analysts price targets for ZLAB or view top-rated stocks among Wall Street analysts. How have ZLAB shares performed in 2024? Zai Lab's stock was trading at $27.33 on January 1st, 2024. Since then, ZLAB stock has decreased by 21.1% and is now trading at $21.55. View the best growth stocks for 2024 here. When is Zai Lab's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our ZLAB earnings forecast. How were Zai Lab's earnings last quarter? Zai Lab Limited (NASDAQ:ZLAB) issued its earnings results on Wednesday, May, 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.93) by $0.38. The firm had revenue of $87.15 million for the quarter, compared to analyst estimates of $77.07 million. Zai Lab had a negative trailing twelve-month return on equity of 40.21% and a negative net margin of 116.45%. During the same period last year, the firm earned ($0.51) earnings per share. What ETFs hold Zai Lab's stock? ETFs with the largest weight of Zai Lab (NASDAQ:ZLAB) stock in their portfolio include Global X China Biotech Innovation ETF (CHB), Amplify Treatments, Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO) and Virtus LifeSci Biotech Products ETF (BBP).Invesco Golden Dragon China ETF (PGJ). What other stocks do shareholders of Zai Lab own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN). When did Zai Lab IPO? Zai Lab (ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO. Who are Zai Lab's major shareholders? Zai Lab's stock is owned by a number of institutional and retail investors. Top institutional investors include Capital World Investors (5.73%), Clearbridge Investments LLC (0.82%), Vivo Capital LLC (0.54%), M&G Plc (0.46%), Russell Investments Group Ltd. (0.30%) and Mirae Asset Global Investments Co. Ltd. (0.11%). Insiders that own company stock include Frazor Titus Edmondson III, Harald Reinhart, John D Diekman, John D Diekman, Joshua L Smiley, Peter Wirth, Rafael Amado, Tao Fu, William Ki Chul Cho, William Lis, Yajing Chen and Ying Du. View institutional ownership trends. How do I buy shares of Zai Lab? Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZLAB) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
